Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT
THE LATEST RESULTS FROM A PHASE I CLINICAL STUDY OF CMG901 AT THE ASCO PLENARY SERIES BY WAY OF ORAL PRESENTATION

This announcement is made by Keymed Biosciences Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Company is pleased to announce that the latest data from a Phase I clinical study of CMG901 (also known as AZD0901), a claudin 18.2 (CLDN18.2) targeted antibody-drug conjugate, in the treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer has been presented by way of oral presentation at the November 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

The KYM901 trial (NCT04805307) was designed to evaluate the safety/tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of CMG901 in patients with advanced solid tumors. As of July 24, 2023, totally 113 patients with G/GEJ cancer received CMG901 at doses of 2.2, 2.6, and 3.0 mg/kg (n=44, 50, and 19, respectively). All patients previously received ≥1 line of prior therapy. The median line of prior therapy was two. 74% of patients previously received PD-1/PD-L1 therapy.

In terms of safety, drug-related grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 54% of patients, and drug-related serious AEs were reported in 31% of patients. 8% of patients had discontinued CMG901 treatment due to TEAEs.

Among 89 evaluable patients with claudin 18.2-positive G/GEJ cancer in 2.2-3.0 mg/kg cohorts, confirmed objective response rate (ORR) and confirmed disease control rate (DCR) were 33% and 70%, respectively. Among others, CMG901 showed a 42% confirmed ORR in 2.2 mg/kg dose cohort, with median progression free survival (mPFS) of 4.8 months, and the median overall survival (mOS) was not reached yet.

Efficacy of CMG901 in Claudin 18.2-positive[#] G/GEJ Cancer				
	Confirmed ORR n/N (%, 95%CI)	Confirmed DCR n/N (%, 95%CI)	mPFS, months (95%CI)	mOS, months (95%CI)
2.2 mg/kg (n=32)	13/31 (42%; 24.5-60.9)	22/31 (71%; 52.0-85.8)	4.8 (3.6-6.0)	NR (6.5-NR)
2.6 mg/kg (n=45)	10/42 (24%; 12.1-39.5)	28/42 (67%; 50.5-80.4)	3.3 (2.2-6.1)	8.5 (6.2-NR)
3.0 mg/kg (n=16)	6/16 (38%; 15.2-64.6)	12/16 (75%; 47.6-92.7)	14.5 (3.0-NR)	NR (5.2-NR)

[#] Claudin 18.2 positivity was defined as CLDN18.2 expression of ≥2+ membrane staining intensity in ≥20% tumor cells

NR=not reached

In this trial, CMG901 had a manageable safety and tolerability profile, and most patients were well-managed by standard treatment management while continuing CMG901 treatment. CMG901 demonstrated promising efficacy in patients with advanced claudin 18.2-positive G/GEJ cancer.

ABOUT CMG901

CMG901 is a potential first-in-class claudin 18.2 targeted antibody conjugated to monomethyl auristatin E (MMAE) payload via a linker, currently being evaluated in a Phase 1 clinical study in advanced solid tumors (gastric and pancreatic). Claudin 18.2 is a promising therapeutic target for advanced G/GEJ cancer. In February 2023, KYM Biosciences Inc. (a 70% non-wholly owned subsidiary of the Group) entered into a global exclusive out-license agreement with AstraZeneca for CMG901. Under the license agreement, AstraZeneca is responsible for the research, development, manufacture and commercialization of CMG901 (also known as AZD0901) globally.

This announcement is made by the Company on a voluntary basis to provide information to the shareholders and potential investors of the Company. There is no assurance that the Company will ultimately develop, launch and/or commercialize the product successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, November 8, 2023

As at the date of this announcement, the Board comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive directors; and Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive directors.